SHIVALIK RASAYAN Latest Share Price (SHIVALIK)
TODAY IN ONE LINE
SHIVALIK dropped 3.8% on above-average volume (1866076.9x avg), lagging Nifty's -0.4% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹498.93 Cr., it trades at a P/E of 37.69. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SHIVALIK RASAYAN flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.19x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Price MomentumStock underperformed, dropping 14.6% over 1Y
- ●Earnings DeclineEPS (TTM) has contracted by 3.2% YoY
- ●Poor Capital ReturnsLow ROE of 3.0%
- ●Promoter SellingPromoter holding decreased by 0.83% QoQ
Latest SHIVALIK RASAYAN News
What changed recently?
Recent events, corporate actions, and announcements.
SHIVALIK RASAYAN valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SHIVALIK RASAYAN, framed against the sector median so the premium or discount is obvious at a glance.
SHIVALIK RASAYAN trades at a P/E of 37.69× and P/B of 0.86×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SHIVALIK RASAYAN technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SHIVALIK RASAYAN — derived from the latest tape, not yesterday's close.
SHIVALIK RASAYAN last traded at ₹306.5 with an intraday range of ₹297.4–₹314.95 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹306.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 350.27 | +43.77 | +14.28% |
| R3 | 332.72 | +26.22 | +8.55% |
| R2 | 323.83 | +17.33 | +5.66% |
| R1 | 315.17 | +8.67 | +2.83% |
| PIVOT | 306.28 | -0.22 | -0.07% |
| CURRENT | 306.50 | — | — |
| S1 | 297.62 | -8.88 | -2.90% |
| S2 | 288.73 | -17.77 | -5.80% |
| S3 | 280.07 | -26.43 | -8.62% |
| S4 | 262.52 | -43.98 | -14.35% |
SHIVALIK is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹304.65–₹314.95
Trading Inside opening range
SHIVALIK RASAYAN financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SHIVALIK RASAYAN — consolidated or standalone — with margins, YoY growth and key ratios inline.
SHIVALIK RASAYAN reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹498.93 Cr. and reported EPS of ₹2.16.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 368 | 368 ▲ 0.0% |
| Sales Growth YoY %Derived | 18.04% | 18.04% |
| Other Income | 4 | 4 ▲ 0.0% |
| Total Income | 372 | 372 ▲ 0.0% |
| 188 | 188 ▲ 0.0% | |
| Gross ProfitDerived | 180 | 180 ▲ 0.0% |
| Gross Margin %Derived | 48.81% | 48.81% |
| 134 | 134 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 46 | 46 ▲ 0.0% |
| OPM %Derived | 12.44% | 12.44% |
| 28 | 28 ▲ 0.0% | |
| Profit Before Tax (PBT) | 21 | 21 ▲ 0.0% |
| 4 | 4 ▲ 0.0% | |
| Effective Tax %Derived | 16.33% | 16.33% |
| Total Profit for Period | 18 | 18 ▲ 0.0% |
| Less: Non-controlling Interests | 6 | 6 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 12 | 12 ▲ 0.0% |
| Net Profit Margin %Derived | 3.30% | 3.30% |
| PAT Growth YoY %Derived | -27.31% | -27.31% |
| Earnings Per Share (EPS ₹) | 7.71 | 7.71 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 351 | 351 ▲ 0.0% |
| Material Cost % of RevenueDerived | 53.53% | 53.53% |
| Employee Cost % of RevenueDerived | 16.45% | 16.45% |
| Other Cost % of RevenueDerived | 19.92% | 19.92% |
| Interest Coverage (x)Derived | 2.81x | 2.81x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | May 2022 | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 171 | 186 ▲ 9.2% | 198 ▲ 6.1% | 215 ▲ 8.7% | 215 ▲ 0.0% | 234 ▲ 9.2% | 234 ▲ 0.0% | 273 ▲ 16.4% | 273 ▲ 0.0% | 312 ▲ 14.2% | 312 ▲ 0.0% | 368 ▲ 18.0% | 368 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | 9.22% | 6.07% | 8.69% | — | 9.17% | 9.17% | 16.44% | 16.44% | 14.21% | 14.21% | 18.04% | 18.04% | |
| Other Income | 8 | 3 ▼ 60.7% | 1 ▼ 64.0% | 4 ▲ 227.7% | 4 ▲ 0.0% | 5 ▲ 25.7% | 5 ▲ 0.0% | 4 ▼ 14.7% | 4 ▲ 0.0% | 8 ▲ 108.9% | 8 ▲ 0.0% | 4 ▼ 50.9% | 4 ▲ 0.0% | |
| Total Income | 179 | 189 ▲ 6.1% | 199 ▲ 4.9% | 218 ▲ 9.9% | 218 ▲ 0.0% | 239 ▲ 9.5% | 239 ▲ 0.0% | 277 ▲ 15.8% | 277 ▲ 0.0% | 320 ▲ 15.6% | 320 ▲ 0.0% | 372 ▲ 16.2% | 372 ▲ 0.0% | |
111 | 114 ▲ 2.2% | 107 ▼ 5.9% | 94 ▼ 11.9% | 94 ▲ 0.0% | 115 ▲ 21.9% | 115 ▲ 0.0% | 140 ▲ 21.9% | 140 ▲ 0.0% | 160 ▲ 14.7% | 160 ▲ 0.0% | 188 ▲ 17.4% | 188 ▲ 0.0% | ||
| Gross ProfitDerived | 59 | 73 ▲ 22.3% | 91 ▲ 24.8% | 121 ▲ 33.0% | 121 ▲ 0.0% | 120 ▼ 0.8% | 120 ▲ 0.0% | 133 ▲ 11.2% | 133 ▲ 0.0% | 151 ▲ 13.7% | 151 ▲ 0.0% | 180 ▲ 18.7% | 180 ▲ 0.0% | |
| Gross Margin %Derived | 34.82% | 39.00% | 45.90% | 56.17% | 56.17% | 51.07% | 51.07% | 48.77% | 48.77% | 48.55% | 48.55% | 48.81% | 48.81% | |
36 | 44 ▲ 22.1% | 53 ▲ 19.6% | 74 ▲ 40.1% | 74 ▲ 0.0% | 77 ▲ 3.9% | 77 ▲ 0.0% | 94 ▲ 22.4% | 94 ▲ 0.0% | 111 ▲ 18.3% | 111 ▲ 0.0% | 134 ▲ 20.4% | 134 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 23 | 29 ▲ 22.6% | 38 ▲ 32.9% | 47 ▲ 23.2% | 47 ▲ 0.0% | 43 ▼ 8.1% | 43 ▲ 0.0% | 39 ▼ 8.8% | 39 ▲ 0.0% | 40 ▲ 2.6% | 40 ▲ 0.0% | 46 ▲ 13.8% | 46 ▲ 0.0% | |
| OPM %Derived | 13.65% | 15.32% | 19.21% | 21.77% | 21.77% | 18.32% | 18.32% | 14.35% | 14.35% | 12.90% | 12.90% | 12.44% | 12.44% | |
5 | 5 ▼ 1.7% | 10 ▲ 103.3% | 14 ▲ 33.0% | 14 ▲ 0.0% | 16 ▲ 18.1% | 16 ▲ 0.0% | 20 ▲ 25.4% | 20 ▲ 0.0% | 25 ▲ 25.5% | 25 ▲ 0.0% | 28 ▲ 13.0% | 28 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 26 | 27 ▲ 1.9% | 29 ▲ 8.4% | 37 ▲ 27.8% | 37 ▲ 0.0% | 32 ▼ 14.3% | 32 ▲ 0.0% | 23 ▼ 26.9% | 23 ▲ 0.0% | 23 ▲ 1.1% | 23 ▲ 0.0% | 21 ▼ 8.3% | 21 ▲ 0.0% | |
5 | 5 ▼ 11.3% | 4 ▼ 11.3% | 3 ▼ 34.4% | 3 ▲ 0.0% | 2 ▼ 32.4% | 2 ▲ 0.0% | 5 ▲ 177.8% | 5 ▲ 0.0% | 3 ▼ 41.3% | 3 ▲ 0.0% | 4 ▲ 17.5% | 4 ▲ 0.0% | ||
| Effective Tax %Derived | 20.01% | 17.42% | 14.25% | 7.32% | 7.32% | 5.78% | 5.78% | 21.95% | 21.95% | 12.75% | 12.75% | 16.33% | 16.33% | |
| Total Profit for Period | 21 | 22 ▲ 5.2% | 25 ▲ 12.5% | 34 ▲ 38.1% | 34 ▲ 0.0% | 30 ▼ 12.9% | 30 ▲ 0.0% | 18 ▼ 39.4% | 18 ▲ 0.0% | 20 ▲ 13.0% | 20 ▲ 0.0% | 18 ▼ 12.0% | 18 ▲ 0.0% | |
| Less: Non-controlling Interests | — | — | — | — | — | — | — | 2 | 2 ▲ 0.0% | 4 ▲ 117.8% | 4 ▲ 0.0% | 6 ▲ 56.5% | 6 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 21 | 22 ▲ 5.2% | 25 ▲ 12.5% | 34 ▲ 38.1% | 34 ▲ 0.0% | 30 ▼ 12.9% | 30 ▲ 0.0% | 16 ▼ 45.2% | 16 ▲ 0.0% | 17 ▲ 2.1% | 17 ▲ 0.0% | 12 ▼ 27.3% | 12 ▲ 0.0% | |
| Net Profit Margin %Derived | 12.28% | 11.83% | 12.55% | 15.95% | 15.95% | 12.72% | 12.72% | 5.99% | 5.99% | 5.36% | 5.36% | 3.30% | 3.30% | |
| PAT Growth YoY %Derived | — | 5.24% | 12.52% | 38.09% | — | -12.90% | -12.90% | -45.16% | -45.16% | 2.05% | 2.05% | -27.31% | -27.31% | |
| Earnings Per Share (EPS ₹) | 15.20 | 16.00 ▲ 5.3% | 18.00 ▲ 12.5% | 23.64 ▲ 31.3% | 23.64 ▲ 0.0% | 20.59 ▼ 12.9% | 20.59 ▲ 0.0% | 10.51 ▼ 49.0% | 10.51 ▲ 0.0% | 10.60 ▲ 0.9% | 10.60 ▲ 0.0% | 7.71 ▼ 27.3% | 7.71 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 5.2% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 2 ▲ 7.4% | 2 ▲ 0.0% | 2 ▲ 1.2% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 152 | 163 ▲ 6.8% | 170 ▲ 4.3% | 182 ▲ 6.9% | 182 ▲ 0.0% | 207 ▲ 14.3% | 207 ▲ 0.0% | 254 ▲ 22.3% | 254 ▲ 0.0% | 297 ▲ 16.9% | 297 ▲ 0.0% | 351 ▲ 18.2% | 351 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 63.60% | 62.10% | 53.42% | 47.46% | 47.46% | 56.58% | 56.58% | 57.17% | 57.17% | 55.63% | 55.63% | 53.53% | 53.53% | |
| Employee Cost % of RevenueDerived | 7.70% | 8.77% | 10.72% | 13.89% | 13.89% | 15.75% | 15.75% | 17.15% | 17.15% | 17.65% | 17.65% | 16.45% | 16.45% | |
| Other Cost % of RevenueDerived | 13.46% | 14.91% | 15.97% | 20.52% | 20.52% | 17.00% | 17.00% | 17.27% | 17.27% | 18.01% | 18.01% | 19.92% | 19.92% | |
| Interest Coverage (x)Derived | 9.86x | 16.86x | 18.65x | 14.32x | 14.32x | 7.22x | 7.22x | 3.51x | 3.51x | 2.62x | 2.62x | 2.81x | 2.81x |
SHIVALIK RASAYAN segment analysis : revenue and profit mix.
Disclosed business segments at SHIVALIK RASAYAN with their share of revenue and profit, switchable between consolidated and standalone reporting.
SHIVALIK RASAYAN discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SHIVALIK RASAYAN.
Our AI distills the core fundamental drivers supporting SHIVALIK RASAYAN, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
SHIVALIK RASAYAN's investment case rests on 9 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Debt-to-equity ratio is very low at 0.18, indicating strong financial health.
Consistent revenue growth. 5-year CAGR of 10.85% and 3-year CAGR of 13.23%.
Robust quarterly sales growth of 19.70% demonstrates strong recent market demand.
Diversified product portfolio across Agrochemicals and Pharmaceutical APIs mitigates risks.
Increasing FII confidence, with holdings rising from 0.04% to 4.38% recently.
Key Risks.
Low profitability ratios. ROE 1.56% and ROCE 5.51% indicate inefficient capital use.
Sharp quarterly profit decline of -54.60% raises concerns about recent performance.
High P/E ratio of 43.76 appears overvalued compared to sector P/E 42.07.
Negative EPS growth over 3 years (-16.36%) and low 5-year growth (0.84%).
Negative annual cash flow per share (-20.46) indicates poor operational cash generation.
Flip Conditions.
Valuation risk. a P/E above 49 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
SHIVALIK RASAYAN peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SHIVALIK RASAYAN is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SHIVALIK RASAYAN chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SHIVALIK RASAYAN — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SHIVALIK RASAYAN delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SHIVALIK RASAYAN over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SHIVALIK RASAYAN stood at 50.4% of traded volume, against a 20-day average of 49.9%.
SHIVALIK RASAYAN announcements: results, concalls, ratings, M&A.
Filings SHIVALIK RASAYAN sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SHIVALIK RASAYAN files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 53 documents below.
Shareholders meeting
Shivalik Rasayan Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 28, 2026. Further, the…
General Updates
Shivalik Rasayan Limited has informed the Exchange about General Updates
Shareholders meeting
Shivalik Rasayan Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 28, 2026
Trading Window
Shivalik Rasayan Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Outcome of Board Meeting
Shivalik Rasayan Limited has informed the Exchange regarding Outcome of Board Meeting held on September 14, 2026.
SHIVALIK RASAYAN dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SHIVALIK RASAYAN has declared, sequenced by announce and record date.
SHIVALIK RASAYAN corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About SHIVALIK RASAYAN: business, sector, key facts.
What SHIVALIK RASAYAN does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SHIVALIK RASAYAN operates in the Pesticides & Agrochemicals industry under the Chemicals sector, listed as NSE: SHIVALIK, BSE: 539148.
Shivalik Rasayan Limited (SRL) is an Indian chemical manufacturing company primarily focused on the production and sale of agrochemicals and pharmaceutical ingredients. A significant portion of their business involves the creation of plant protection chemicals for the agricultural sector. This includes the manufacture of key active ingredients such as Dimethoate technical and Malathion technical. Dimethoate technical serves as a base for creating formulations used to control insects and mites affecting various crops, while Malathion technical, an organophosphate insecticide, finds application in controlling pests on numerous food and feed crops. Their expertise extends to the broader manufacturing of organophosphorus-based insecticides and other related chemicals.
Beyond agrochemicals, SRL also plays a substantial role in the pharmaceutical industry. They are involved in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs). These APIs cater to a diverse range of therapeutic areas, including oncology (cancer treatment), antiretroviral drugs (ARVs) used to combat HIV/AIDS, cardiovascular medications, treatments for metabolic disorders, and immunology-related drugs. This diversification into pharmaceutical APIs significantly broadens SRL’s product portfolio and market reach.
In addition to their own product lines, SRL offers custom chemical manufacturing services. This aspect of their business allows them to cater to the specific needs of other companies requiring specialized chemical synthesis or formulation. This contract manufacturing capability adds another revenue stream and demonstrates their flexibility and expertise in chemical processing. The company's established infrastructure and experience in chemical production likely make them a competitive choice for companies outsourcing their manufacturing needs.
Established in 1979 and headquartered in New Delhi, India, Shivalik Rasayan Limited has a long history in the chemical industry. Their integrated approach encompassing both agrochemicals and pharmaceutical APIs positions them uniquely in the Indian market. This strategy allows for potential synergies between their divisions, and diversification mitigates risks associated with relying heavily on any single market sector. The company's continued success will likely depend on its ability to innovate, adapt to evolving market demands, and maintain its competitive edge in both the agricultural and pharmaceutical sectors.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- ASTEC LIFESCIENCES (ASTEC) Share PricePeer
- BHAGIRADHA CHEM & INDS L (BHAGCHEM) Share PricePeer
- BHARAT RASAYAN (BHARATRAS) Share PricePeer
- DHANUKA AGRITECH (DHANUKA) Share PricePeer
- DHARMAJ CROP GUARD (DHARMAJ) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SHIVALIK RASAYAN (SHIVALIK).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SHIVALIK RASAYAN (SHIVALIK)?
The current share price of SHIVALIK RASAYAN (SHIVALIK) is ₹306.50. Today, the stock has declined by ₹12.00 (3.77%), trading in a range of ₹297.40 to ₹314.95. The stock opened at ₹313.30 with a trading volume of 1,21,295 shares.
02Is SHIVALIK RASAYAN stock a good investment for long-term?
SHIVALIK RASAYAN can be considered for long-term investment based on several factors. The company has a market capitalization of ₹498.93 Cr., P/E ratio of 37.69, ROE of 3%, and ROCE of 4.25%. The dividend yield stands at 0.16%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SHIVALIK RASAYAN stock?
The 52-week high price of SHIVALIK RASAYAN (SHIVALIK) is ₹471.00, while the 52-week low is ₹206.75. Currently trading at ₹306.50, the stock is 48.25% above its 52-week low and 34.93% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SHIVALIK RASAYAN stock at the current price?
Whether to buy SHIVALIK RASAYAN stock at ₹306.50 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.69 and P/B ratio of 0.86. Today's performance shows a loss of 3.77%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SHIVALIK RASAYAN and when is the next dividend?
SHIVALIK RASAYAN offers a dividend yield of 0.16%, which means for every ₹100 invested at the current price of ₹306.50, you can expect to receive approximately ₹0.16 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SHIVALIK RASAYAN?
SHIVALIK RASAYAN's key financial metrics include: P/E Ratio: 37.69, P/B Ratio: 0.86, ROE: 3%, ROCE: 4.25%, Dividend Yield: 0.16%, EPS: ₹2.16, Book Value: ₹380.38, and Debt-to-Equity: 0.19. The company's market cap stands at ₹498.93 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SHIVALIK RASAYAN stock performing today in the market?
SHIVALIK RASAYAN stock opened at ₹313.30 and is currently trading at ₹306.50, showing a decline of ₹12.00 (3.77%). The intraday high is ₹314.95 and low is ₹297.40. The trading volume stands at 1,21,295 shares, indicating moderate market participation today.
08What is the P/E ratio of SHIVALIK RASAYAN and what does it indicate?
SHIVALIK RASAYAN has a Price-to-Earnings (P/E) ratio of 37.69, which means investors are willing to pay 37.69 for every ₹1 of earnings. With an EPS of ₹2.16, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SHIVALIK RASAYAN (SHIVALIK) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.